Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435509 | 0.76 | TFPI2 (0.58) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL7024843 | 0.76 | TFPI2 (0.58) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL29506395 | 0.74 | NOTUM (1.00) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL15702556 | 0.74 | NOTUM (0.66) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL41252 | 0.74 | NOTUM (1.00) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL10477477 | 0.74 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL1151123 | 0.74 | NOTUM (0.70) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL3834965 | 0.74 | NOTUM (0.65) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| SCHEMBL29428949 | 0.74 | NOTUM (0.65) | NOTUMTSHRRAB9AL3MBTL1TFPI2 | |
| Ammonia Solution, Strong SCHEMBL27633395 | 0.73 | NOTUM (0.96) | NOTUMTSHRRAB9AL3MBTL1TFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833824-B1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20110065685-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-03-17 | — | — | US | disclosed |
| US-7750039-B2 | Indoles are cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2010-07-06 | — | — | US | disclosed |
| US-7560481-B2 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-06-11 | — | — | US | disclosed |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBVIE INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149501-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | CNR2, CNR1, OPRL1 | NOTUM 1930/4885TSHR 1295/4885RAB9A 2488/4885 |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | CNR2, CNR1, TRPV1 | NOTUM 2326/4885TSHR 2484/4885RAB9A 4303/4885 |
| US-20110065685-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | CNR2, CNR1, OPRL1 | NOTUM 1930/4885TSHR 1295/4885RAB9A 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.